Jump to content


Photo

New medication NEV-801 to treat CML

NEV-801 CML cronic myeloid leukemia

  • Please log in to reply
6 replies to this topic

#1 survenant

survenant

    Advanced Member

  • Members
  • PipPipPip
  • 98 posts

Posted 03 February 2017 - 12:05 PM

"During its pre-clinical proof-of-concept studies, NEV-801 showed exciting potential, including curative effects, to treat Chronic Myeloid Leukemia that had become resistant to the gold-standard therapy (imatinib), as well as advanced colon cancer that had become resistant to multiple therapies. No bone-marrow toxicity or gastro-intestinal side effects were observed at the highest administered doses in pre-clinical studies"

Extract of http://www.checkorph...ing-cancer-drug

 

See more about NEV-801



#2 kat73

kat73

    Advanced Member

  • Members
  • PipPipPip
  • 884 posts
  • LocationWashington, DC area

Posted 03 February 2017 - 12:49 PM

Thanks, Survenant!  I've come to rely on you to ferret out all the new stuff - this looks really good!  Even if it doesn't pan out, it's great to hear that "they" are all still trying for a cure - and this one's actually in a clinical trial.  YAY!!!  Keep us posted.


Dx July 2009 on routine physical.  WBC 94.  Started Gleevec 400 mg Sept 2009.  MMR at 2yrs.  Side effects (malaise, depression/anxiety, fatigue, nausea, periorbital edema) never improved.  Kidney issues developed because of Gleevec.  Switched to Sprycel 70 mg in Aug 2011.  Above side effects disappeared or improved.  Have been MR3.5 - 4.5 ever since.  Two untreated pleural effusions followed by one treated by stopping Sprycel Jan 2017.  After 9 weeks, PCR showed loss of MMR; re-started Sprycel at 50 mg and in 3 months was back to <0.01% IS.  Pleural effusion returned within a couple of months, same as before (moderate, left side only).  Stopped Sprycel 50 mg for 12 weeks; pleural effusion resolved.  At about a monthoff the drug, PCR was 0.03; at 11 weeks it was 2.06 - lost CCyR? Have returned to 50 mg Sprycel for 3 weeks, intending to reduce to 20 mg going forward.


#3 thatguy

thatguy

    Advanced Member

  • Members
  • PipPipPip
  • 318 posts
  • LocationWild west

Posted 03 February 2017 - 05:57 PM

Nice!
3/25/2015- Dx'ed by FISH : 85% of cells dual-fusion signals, 7% with tri-fusion signals, WBC 212,000. Started Gleevec 400mg.... Calculated .93 SOKAL

08/17/2015- 14.793 % I.S P210 (quest)
10/15/2015- 3.313 % I.S (quest)
12/23/2015- 1.891 % I.S (quest)
1/07/2016- Tasigna 300mg 2x daily
1/14/2016- 4.414 % I.S P210- City Of Hope lab, mutation negative.
1/26/2016- 1.589 % I.S (quest)
2/22/2016- 1.719 % I.S (quest)
2/29/2016- 1.133 % I.S (quest)
3/03/2016- Tasigna 400mg 2x daily.
3/29/2016- 0.663 % I.S (quest)
4/27/2016- 0.781 % I.S (quest)
5/04/2016- 0.652 % I.S.(quest)
5/24/2016- 0.501 % I.S (quest)
6/28/2016-0.534 % I.S (quest)
7/15/2016-0.881 % I.S (quest)
7/22/2016- Bosulif 500mg
7/28/2016- t315i test- Negative
8/22/2016-0.432 % I.S (quest )
11/15/2016-0.325 % I.S (quest)
2/1/2017- .0445% i.s (genoptix)
5/6/2017- .0968% i.s (genoptix)
5/12/2017- .12 % i.s (quest).
6/4/2017- .083% i.s (quest)
6/11/2017- .0295% i.s (genoptix)
8/5/2017- .0501% i.s (genoptix)
11/6/2017- .0270% i.s (genoptix)

#4 missjoy

missjoy

    Advanced Member

  • Members
  • PipPipPip
  • 122 posts

Posted 04 February 2017 - 02:42 PM

Abstract
Recent strategies for treating chronic myelogenous leukemia (CML) patients have focused on investigating new combinations of tyrosine kinase inhibitors (TKIs) as well as identifying novel translational research agents that can eradicate CML leukemia-initiating cells (CML-LICs). However, little is known about the therapeutic benefits such CML-LIC targeting therapies might bring to CML patients. In this study, we investigated the therapeutic potential of EW-7197, an orally bioavailable TGF-β signaling inhibitor which has recently been approved as an Investigational New Drug (NIH, USA), to suppress CML-LICs in vivo. Compared to TKI treatment alone, administration of TKI plus EW-7197 to CML-affected mice significantly delayed disease relapse and prolonged survival. Notably, the combined administration of EW-7197 plus TKI was effective in eliminating CML-LICs even if they expressed the TKI-resistant T315I mutant BCR-ABL1 oncogene. Collectively, these results indicate that EW-7197 may be a promising candidate for a new therapeutic that can greatly benefit CML patients by working in combination with TKIs to eradicate CML-LICs.

#5 survenant

survenant

    Advanced Member

  • Members
  • PipPipPip
  • 98 posts

Posted 05 February 2017 - 11:22 AM

Thank you Missjoy for Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells

 

See also

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

 



#6 r06ue1

r06ue1

    Advanced Member

  • Members
  • PipPipPip
  • 426 posts
  • LocationEarth, Solar System, Milky Way, Local Group, Virgo Supercluster, Laniakea

Posted 06 February 2017 - 06:32 AM

Clinical Trial

https://clinicaltria...m=NEV801&rank=1

 

I guess they are testing this on multiple types of cancer, no mention of CML in the study record.  

 

Also, this appears to be an immunotherapy.


08/2015 Initial PCR: 66.392%

12/2015 PCR: 1.573%

03/2016 PCR: 0.153%

06/2016 PCR: 0.070%

09/2016 PCR: 0.052%

12/2016 PCR: 0.036%

03/2017 PCR: 0.029%

06/2017 PCR: 0.028%

09/2017 PCR: 0.025%

12/2017 PCR: 0.018%

 

 

Taking Imatinib 400 mg


#7 TeddyB

TeddyB

    Advanced Member

  • Members
  • PipPipPip
  • 203 posts

Posted 09 February 2017 - 03:31 PM

Thank you survenant. This looks promising.







Also tagged with one or more of these keywords: NEV-801, CML, cronic myeloid leukemia

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users